Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880384 | 0.90 | MEN1 (0.53) | NPC1MEN1KMT2APOLBGLA | |
| SCHEMBL29594778 | 0.84 | NPC1 (0.57) | NPC1MEN1KMT2APOLBGLA | |
| SCHEMBL2880232 | 0.84 | MAPT (0.62) | NPC1MEN1KMT2APOLBCYP11B1 | |
| SCHEMBL2881602 | 0.83 | CYP11B1 (0.56) | NPC1MEN1KMT2APOLBGLA | |
| SCHEMBL5024162 | 0.81 | POLB (0.58) | NPC1MEN1KMT2APOLBGLA | |
| SCHEMBL2882290 | 0.80 | MAPT (0.53) | NPC1MEN1KMT2APOLBGLA | |
| SCHEMBL852214 | 0.80 | POLB (0.57) | NPC1MEN1KMT2APOLBGLA | |
| SCHEMBL9464873 | 0.80 | POLB (0.57) | NPC1MEN1KMT2APOLBGLA | |
| SCHEMBL30264508 | 0.80 | POLB (0.57) | NPC1MEN1KMT2APOLBGLA | |
| SCHEMBL26005660 | 0.79 | MAPT (0.63) | POLBCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102746240-B | anti-infective pyrimidines and uses thereof | 艾伯维巴哈马有限公司 | 2017-10-03 | — | — | CN | disclosed |
| EP-2639226-B1 | Anti-infective pyrimidines and uses thereof | ABBVIE BAHAMAS LTD (BS) | 2016-08-31 | — | — | EP | disclosed |
| US-9139536-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2368882-B1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBVIE BAHAMAS LTD (BS) | 2014-08-13 | — | — | EP | disclosed |
| EP-2725015-A1 | Uracil or thymine derivative for treating hepatitis c | AbbVie Bahamas Ltd. (BS) | 2014-04-30 | — | — | EP | disclosed |
| EP-2639226-A1 | Anti-infective pyrimidines and uses thereof | ABBOTT LABORATORIES (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8501238-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010127855-A1 | SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127855-A1 | SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2010-11-11 | — | — | WO | disclosed |
| CN-101842360-A | Anti-infective pyrimidines and uses thereof | ABBOTT LAB | 2010-09-22 | — | — | CN | disclosed |
| EP-2222646-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| CN-101801935-A | Uracil or thymine derivatives for the treatment of hepatitis C | ABBOTT LAB | 2010-08-11 | — | — | CN | disclosed |
| EP-2203431-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | TRPV1, UTS2R, CNR2 | NPC1 1285/4885MEN1 4682/4885KMT2A 3101/4885 |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | NPC1 188/4885MEN1 3463/4885KMT2A 4704/4885 |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | MPO, ELANE, LPO | NPC1 188/4885MEN1 3508/4885KMT2A 4715/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | NPC1 188/4885MEN1 3463/4885KMT2A 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.